{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T12:08:46Z","timestamp":1772539726215,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-04929-9","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:31:35Z","timestamp":1751603495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Determinants of polypharmacy among ambulatory cardiovascular disease patients in Iluababora and Buno Bedele Zones, Ethiopia: prospective observational study"],"prefix":"10.1186","volume":"25","author":[{"given":"Birbirsa","family":"Sefera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadesse","family":"Sheleme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mesay","family":"Dechasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemechu Gelana","family":"Ararame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"4929_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1201\/b23266-2","volume":"1","author":"TA Gaziano","year":"2022","unstructured":"Gaziano TA. Cardiovascular diseases worldwide. Public Health Approach Cardiovasc Dis Prev Manag. 2022;1:8\u201318.","journal-title":"Public Health Approach Cardiovasc Dis Prev Manag"},{"issue":"1","key":"4929_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrcardio.2010.162","volume":"8","author":"JL Fleg","year":"2011","unstructured":"Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Reviews Cardiol. 2011;8(1):13\u201328.","journal-title":"Nat Reviews Cardiol"},{"issue":"9","key":"4929_CR3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.5694\/mja2.50120","volume":"210","author":"P Leong","year":"2019","unstructured":"Leong P, Macdonald MI, Ko BS, Bardin PG. Coexisting chronic obstructive pulmonary disease and cardiovascular disease in clinical practice: a diagnostic and therapeutic challenge. Med J Aust. 2019;210(9):417\u201323.","journal-title":"Med J Aust"},{"issue":"1","key":"4929_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4103\/0971-6580.94506","volume":"19","author":"S Rambhade","year":"2012","unstructured":"Rambhade S, Chakarborty A, Shrivastava A, Patil UK, Rambhade A. A survey on polypharmacy and use of inappropriate medications. Toxicol Int. 2012;19(1):68.","journal-title":"Toxicol Int"},{"key":"4929_CR5","doi-asserted-by":"crossref","unstructured":"Muth C, Blom JW, Smith SM, Johnell K, Gonzalez-Gonzalez AI, Nguyen TS, et al. Evidence supporting the best clinical management of patients with Multimorbidity and polypharmacy: a systematic guideline review and expert consensus. Wiley Online Library; 2019. pp. 272\u201388.","DOI":"10.1111\/joim.12842"},{"key":"4929_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6963-12-170","volume":"12","author":"N van Sluisveld","year":"2012","unstructured":"van Sluisveld N, Zegers M, Natsch S, Wollersheim H. Medication reconciliation at hospital admission and discharge: insufficient knowledge, unclear task reallocation and lack of collaboration as major barriers to medication safety. BMC Health Serv Res. 2012;12:1\u201312.","journal-title":"BMC Health Serv Res"},{"issue":"13","key":"4929_CR7","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.21608\/ejchem.2024.337875.10834","volume":"67","author":"BMA Alhozim","year":"2024","unstructured":"Alhozim BMA, Almutairi ET, Albutyan ZY, Alzahrani NA, Alonizy MM, Albutyan LY, et al. The impact of polypharmacy on drug efficacy and safety in geriatric populations. Egypt J Chem. 2024;67(13):1533\u201340.","journal-title":"Egypt J Chem"},{"issue":"1","key":"4929_CR8","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1186\/s12877-022-03346-3","volume":"22","author":"J Scheel","year":"2022","unstructured":"Scheel J, Luttenberger K, Graessel E, Kratzer A, Donath C. Predictors of falls and hospital admissions in people with cognitive impairment in day-care: role of multimorbidity, polypharmacy, and potentially inappropriate medication. BMC Geriatr. 2022;22(1):682.","journal-title":"BMC Geriatr"},{"key":"4929_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10865-007-9147-y","volume":"31","author":"KS Ingersoll","year":"2008","unstructured":"Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31:213\u201324.","journal-title":"J Behav Med"},{"key":"4929_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12875-017-0642-0","volume":"18","author":"M Molokhia","year":"2017","unstructured":"Molokhia M, Majeed A. Current and future perspectives on the management of polypharmacy. BMC Fam Pract. 2017;18:1\u20139.","journal-title":"BMC Fam Pract"},{"issue":"6","key":"4929_CR11","first-page":"1","volume":"7","author":"JA Haroun","year":"2023","unstructured":"Haroun JA, Sneed K, Pathak Y. Optimizing medication and patient health through deprescribing practices. Nur Prim Care. 2023;7(6):1\u20138.","journal-title":"Nur Prim Care"},{"issue":"1","key":"4929_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1472-8206.2009.00757.x","volume":"24","author":"M Volpe","year":"2010","unstructured":"Volpe M, Chin D, Paneni F. The challenge of polypharmacy in cardiovascular medicine. Fundam Clin Pharmacol. 2010;24(1):9\u201317.","journal-title":"Fundam Clin Pharmacol"},{"issue":"8","key":"4929_CR13","doi-asserted-by":"publisher","first-page":"e0182613","DOI":"10.1371\/journal.pone.0182613","volume":"12","author":"CA Gronde Tvd, Uyl-de Groot","year":"2017","unstructured":"Gronde Tvd, Uyl-de Groot CA, Pieters T. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: a systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. PLoS ONE. 2017;12(8):e0182613.","journal-title":"PLoS ONE"},{"issue":"9","key":"4929_CR14","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1161\/HYPERTENSIONAHA.122.19222","volume":"79","author":"P Muntner","year":"2022","unstructured":"Muntner P, Miles MA, Jaeger BC, Hannon L III, Hardy ST, Ostchega Y, et al. Blood pressure control among US adults, 2009 to 2012 through 2017 to 2020. Hypertension. 2022;79(9):1971\u201380.","journal-title":"Hypertension"},{"issue":"25S","key":"4929_CR15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jacc.2012.11.002","volume":"60","author":"LJ Laslett","year":"2012","unstructured":"Laslett LJ, Alagona P, Clark BA, Drozda JP, Saldivar F, Wilson SR, et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American college of cardiology. J Am Coll Cardiol. 2012;60(25S):S1\u201349.","journal-title":"J Am Coll Cardiol"},{"key":"4929_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13690-015-0095-7","volume":"73","author":"D Walckiers","year":"2015","unstructured":"Walckiers D, Van der Heyden J, Tafforeau J. Factors associated with excessive polypharmacy in older people. Archives Public Health. 2015;73:1\u201312.","journal-title":"Archives Public Health"},{"issue":"3","key":"4929_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/fampra\/17.3.261","volume":"17","author":"L Veehof","year":"2000","unstructured":"Veehof L, Stewart R, Haaijer-Ruskamp F, Jong BM-d. The development of polypharmacy. A longitudinal study. Fam Pract. 2000;17(3):261\u20137.","journal-title":"Fam Pract"},{"key":"4929_CR18","first-page":"435","volume-title":"Polypharmacy and medication adherence","author":"M Lavrador","year":"2023","unstructured":"Lavrador M, Cabral AC, Castel-Branco M, Figueiredo IV, Fernandez-Llimos F. Polypharmacy and medication adherence. Aging: Elsevier; 2023. pp. 435\u201353."},{"issue":"1","key":"4929_CR19","doi-asserted-by":"publisher","first-page":"17641","DOI":"10.1038\/s41598-023-45095-2","volume":"13","author":"TA Kitaw","year":"2023","unstructured":"Kitaw TA, Haile RN. Prevalence of polypharmacy among older adults in ethiopia: a systematic review and meta-analysis. Sci Rep. 2023;13(1):17641.","journal-title":"Sci Rep"},{"issue":"6","key":"4929_CR20","doi-asserted-by":"publisher","first-page":"e0234000","DOI":"10.1371\/journal.pone.0234000","volume":"15","author":"YG Tefera","year":"2020","unstructured":"Tefera YG, Alemayehu M, Mekonnen GB. Prevalence and determinants of polypharmacy in cardiovascular patients attending outpatient clinic in Ethiopia university hospital. PLoS ONE. 2020;15(6):e0234000.","journal-title":"PLoS ONE"},{"key":"4929_CR21","doi-asserted-by":"crossref","unstructured":"Dunlay SM, Chamberlain AM. Multimorbidity in older patients with cardiovascular disease. Curr Cardiovasc Risk Rep. 2016;10.","DOI":"10.1007\/s12170-016-0491-8"},{"issue":"3","key":"4929_CR22","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jacc.2022.08.754","volume":"81","author":"W Committee","year":"2023","unstructured":"Committee W, Birtcher KK, Allen LA, Anderson JL, Bonaca MP, Gluckman TJ, et al. 2022 ACC expert consensus decision pathway for integrating atherosclerotic cardiovascular disease and Multimorbidity treatment: a framework for pragmatic, patient-centered care: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2023;81(3):292\u2013317.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"4929_CR23","doi-asserted-by":"publisher","first-page":"e015496","DOI":"10.1136\/bmjopen-2016-015496","volume":"7","author":"SM Abebe","year":"2017","unstructured":"Abebe SM, Andargie G, Shimeka A, Alemu K, Kebede Y, Wubeshet M, et al. The prevalence of non-communicable diseases in Northwest ethiopia: survey of Dabat health and demographic surveillance system. BMJ Open. 2017;7(10):e015496.","journal-title":"BMJ Open"},{"key":"4929_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12877-018-0795-2","volume":"18","author":"MJ Rawle","year":"2018","unstructured":"Rawle MJ, Richards M, Davis D, Kuh D. The prevalence and determinants of polypharmacy at age 69: a British birth cohort study. BMC Geriatr. 2018;18:1\u201312.","journal-title":"BMC Geriatr"},{"key":"4929_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-017-2793-z","volume":"17","author":"J Castioni","year":"2017","unstructured":"Castioni J, Marques-Vidal P, Abolhassani N, Vollenweider P, Waeber G. Prevalence and determinants of polypharmacy in switzerland: data from the CoLaus study. BMC Health Serv Res. 2017;17:1\u20139.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"4929_CR26","doi-asserted-by":"publisher","first-page":"e98043","DOI":"10.1371\/journal.pone.0098043","volume":"9","author":"H-A Kim","year":"2014","unstructured":"Kim H-A, Shin J-Y, Kim M-H, Park B-J. Prevalence and predictors of polypharmacy among Korean elderly. PLoS ONE. 2014;9(6):e98043.","journal-title":"PLoS ONE"},{"key":"4929_CR27","doi-asserted-by":"crossref","unstructured":"Assefa YA, Kedir A, Kahaliw W. Survey on polypharmacy and drug-drug interactions among elderly people with cardiovascular diseases at Yekatit 12 hospital, Addis Ababa, Ethiopia. Integr Pharm Res Pract. 2020:1\u20139.","DOI":"10.2147\/IPRP.S231286"},{"key":"4929_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00228-010-0940-0","volume":"67","author":"E Pappa","year":"2011","unstructured":"Pappa E, Kontodimopoulos N, Papadopoulos A, Tountas Y, Niakas D. Prescribed-drug utilization and polypharmacy in a general population in greece: association with sociodemographic, health needs, health-services utilization, and lifestyle factors. Eur J Clin Pharmacol. 2011;67:185\u201392.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"4929_CR29","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s12872-022-02872-7","volume":"22","author":"P Mohsenzadeh","year":"2022","unstructured":"Mohsenzadeh P, Ardekani A, Poustchi H, Mohammadi Z, Abdipour Mehrian SR, Bazrafshan Drissi H, et al. Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran. BMC Cardiovasc Disord. 2022;22(1):435.","journal-title":"BMC Cardiovasc Disord"},{"key":"4929_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12877-021-02183-0","volume":"21","author":"M Sheikh-Taha","year":"2021","unstructured":"Sheikh-Taha M, Asmar M. Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the united States. BMC Geriatr. 2021;21:1\u20136.","journal-title":"BMC Geriatr"},{"issue":"9","key":"4929_CR31","doi-asserted-by":"publisher","first-page":"e008656","DOI":"10.1136\/bmjopen-2015-008656","volume":"5","author":"F Moriarty","year":"2015","unstructured":"Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in ireland: a repeated cross-sectional study. BMJ Open. 2015;5(9):e008656.","journal-title":"BMJ Open"},{"issue":"4","key":"4929_CR32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/ehjcvp\/pvz014","volume":"5","author":"OI Woudstra","year":"2019","unstructured":"Woudstra OI, Kuijpers JM, Meijboom FJ, Post MC, Jongbloed MR, Duijnhouwer AL, et al. High burden of drug therapy in adult congenital heart disease: polypharmacy as marker of morbidity and mortality. Eur Heart journal-Cardiovascular Pharmacotherapy. 2019;5(4):216\u201325.","journal-title":"Eur Heart journal-Cardiovascular Pharmacotherapy"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04929-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04929-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04929-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:31:39Z","timestamp":1751603499000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04929-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4929"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04929-9","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"14 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical clearance was obtained from the technical and ethical review committee of the College of health sciences, Mattu University (Phar199\/16). Participation of patients in this study was entirely voluntary and confidential. Private information like name and address were protected. Non-participation didn\u2019t affect participants\u2019 care at the ward. Each participant was asked to sign a written informed consent before data collection. The right of participants to withdraw from the interview or not to participate was respected. All methods were performed in accordance with the relevant guidelines and regulations (Declaration of Helsinki).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"468"}}